Changing the treatment paradigm in myelodysplastic syndromes.

@article{Mufti2008ChangingTT,
  title={Changing the treatment paradigm in myelodysplastic syndromes.},
  author={Ghulam J. Mufti and T. L. Chen},
  journal={Cancer control : journal of the Moffitt Cancer Center},
  year={2008},
  volume={15 Suppl},
  pages={
          14-28
        }
}
The treatment algorithm for the patient with myelodysplastic syndrome (MDS) is in the process of being revitalized based on recent results of clinical trials. Historically, the goal for lower-risk patients was hematologic improvement, and disease modification was reserved for patients in the higher-risk category. Recent data now favor shifting emphasis away from supportive care alone and toward altering the disease course and prolonging survival, particularly in patients with intermediate-2 and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

Iron overload in myelodysplastic syndromes: diagnosis and management.

  • Cancer control : journal of the Moffitt Cancer Center
  • 2010

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

Similar Papers

Loading similar papers…